SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Class Action Against Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Lead Plaintiff Deadline: May 13, 2019
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the "Company") (CRBP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Corbussecuritiesduring the period between November 14, 2016 through February 28, 2019, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/crbp.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statementsand/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/crbp. or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Corbusyou have until May 13, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/538934/SHAREHOLDER-ALERT--Bronstein-Gewirtz-Grossman-LLC-Announces-Class-Action-Against-Corbus-Pharmaceuticals-Holdings-Inc-CRBP-and-Lead-Plaintiff-Deadline-May-13-2019
